HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(R)- (N- (3- (4'- fluorophenyl)- 3- (4'- phenylphenoxy)propyl))sarcosine

a potent, selective inhibitor of the hGlyT1 glycine transporter

Also Known As:

ALX 5407; ALX-5407

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - N-substituted Glycines
      - Sarcosine: 281
        (R)-(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl))sarcosine: 5

Experts

1.	Belliveau, Sébastien: 2 articles (08/2022 - 11/2021)
2.	Frouni, Imane: 2 articles (08/2022 - 11/2021)
3.	Huot, Philippe: 2 articles (08/2022 - 11/2021)
4.	Bourgeois-Cayer, Élodie: 1 article (08/2022)
5.	Bédard, Dominique: 1 article (08/2022)
6.	Hadj-Youssef, Shadi: 1 article (08/2022)
7.	Hamadjida, Adjia: 1 article (08/2022)
8.	Kang, Woojin: 1 article (08/2022)
9.	Kwan, Cynthia: 1 article (08/2022)
10.	Ohlund, Leanne: 1 article (08/2022)

Related Diseases

1.	Dyskinesias (Dyskinesia) 11/05/2021 - "In combination with L-DOPA, ALX-5407 0.1 and 1 mg/kg significantly reduced the severity of dyskinesia, by 51% and 41% (both P < 0.001), when compared to vehicle. " 11/05/2021 - "Following repeated administration of L-DOPA to induce dyskinesia and PLBs, they underwent acute challenges of the glycine transporter 1 (GlyT1) inhibitor ALX-5407 (0.01, 0.1 and 1 mg/kg) or vehicle, in combination with L-DOPA, after which the severity of dyskinesia, PLBs and parkinsonian disability was evaluated. " 08/15/2022 - "We have previously demonstrated that glycine transporter 1 (GlyT1) inhibition with ALX-5407 reduces dyskinesia and slightly improves parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. " 11/05/2021 - "Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset."
2.	Neuralgia (Stump Neuralgia) 11/21/2008 - "In the present study, we investigated the effects of the spinally applied glycine transporter inhibitors ALX 5407 (GlyT1) and ALX 1393 (GlyT2) on nociceptive behavior in the chronic constriction injury model of neuropathic pain in male Wistar rats. "
3.	Parkinsonian Disorders (Parkinsonism) 08/15/2022 - "We have previously demonstrated that glycine transporter 1 (GlyT1) inhibition with ALX-5407 reduces dyskinesia and slightly improves parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. " 11/05/2021 - "Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset."
4.	Schizophrenia (Dementia Praecox) 04/01/2005 - "Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia."
5.	Psychotic Disorders (Schizoaffective Disorder) 11/05/2021 - "Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Glycine Plasma Membrane Transport Proteins
3.	ALX 1393
4.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
5.	Serine (L-Serine)
6.	Glycine (Aminoacetic Acid)
7.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
8.	Clozapine (Clozaril)
9.	L 701324